Toby Ferguson (Biogen)

article

Rare disease spotlight: first EU-approved treatment for Friedreich’s ataxia

In this exclusive article, Biogen’s Vice President and Head of…

29 February 2024 | By Catherine Eckford (European Pharmaceutical Review)

In this exclusive article, Biogen’s Vice President and Head of the Neuromuscular Development Unit, Dr Toby Ferguson, discusses the current rare disease landscape and recent developments in treating Friedreich’s ataxia (FA).

article

Converging knowledge and technology to transform neuromuscular disease treatment

With the emergence of innovative therapeutic technologies and progress in…

19 December 2022 | By Hannah Balfour (European Pharmaceutical Review)

With the emergence of innovative therapeutic technologies and progress in the genetic understanding of diseases, Biogen’s Toby Ferguson explains why it is a promising time for the development of therapies for neuromuscular conditions such as amyotrophic lateral sclerosis (ALS).